Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team
Manage episode 306741498 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial. Upon completion of this CE activity, participants will be able to: Interpret the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Utilize multidisciplinary management strategies for localized and diffuse TGCT that include collaboration between oncologists, orthopedic surgeons, advanced practice clinicians, and other relevant professionals, Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients for whom continued surgery is unlikely to produce clinical benefits, Manage safety and dosing considerations with targeted agents in the setting of TGCT.